Analysts Set TransMedics Group, Inc. (NASDAQ:TMDX) Target Price at $124.18

TransMedics Group, Inc. (NASDAQ:TMDX) has been assigned an average rating of “Hold” from the thirteen brokerages that are currently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, six have issued a hold rating and six have given a buy rating to the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $124.1818.

A number of analysts have weighed in on TMDX shares. Stifel Nicolaus increased their price target on TransMedics Group from $75.00 to $80.00 and gave the stock a “hold” rating in a report on Thursday, June 18th. TD Cowen restated a “buy” rating and issued a $120.00 target price on shares of TransMedics Group in a report on Wednesday, July 1st. UBS Group cut their price target on shares of TransMedics Group from $80.00 to $77.00 and set a “neutral” rating on the stock in a report on Wednesday, August 5th. Weiss Ratings cut TransMedics Group from a “hold (c)” rating to a “hold (c-)” rating in a research report on Tuesday, July 28th. Finally, Zacks Research downgraded shares of TransMedics Group from a “hold” rating to a “strong sell” rating in a research report on Monday, July 6th.

Insider Buying and Selling at TransMedics Group

In other news, Director Thomas J. Gunderson sold 9,624 shares of the company’s stock in a transaction on Monday, June 15th. The shares were sold at an average price of $75.06, for a total value of $722,377.44. Following the transaction, the director owned 16,642 shares of the company’s stock, valued at approximately $1,249,148.52. This represents a 36.64% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 6.90% of the stock is currently owned by corporate insiders.

Institutional Trading of TransMedics Group

A number of hedge funds have recently bought and sold shares of TMDX. Silvant Capital Management LLC purchased a new stake in shares of TransMedics Group during the second quarter valued at approximately $26,000. Harvest Fund Management Co. Ltd bought a new position in shares of TransMedics Group in the 3rd quarter worth approximately $29,000. North Star Investment Management Corp. bought a new stake in shares of TransMedics Group during the 1st quarter valued at $30,000. Ascentis Independent Advisors purchased a new stake in TransMedics Group in the first quarter worth about $30,000. Finally, Allworth Financial LP grew its stake in shares of TransMedics Group by 74.3% in the 3rd quarter. Allworth Financial LP now owns 265 shares of the company’s stock worth $30,000 after buying an additional 113 shares during the last quarter. Institutional investors own 99.67% of the company’s stock.

TransMedics Group Price Performance

TMDX stock opened at $90.85 on Friday. The company’s 50-day moving average price is $77.05 and its two-hundred day moving average price is $95.32. The firm has a market cap of $3.14 billion, a P/E ratio of 23.35 and a beta of 1.90. The company has a quick ratio of 6.07, a current ratio of 6.62 and a debt-to-equity ratio of 1.62. TransMedics Group has a 12 month low of $60.10 and a 12 month high of $156.00.

TransMedics Group (NASDAQ:TMDX) last posted its earnings results on Tuesday, August 4th. The company reported $0.44 earnings per share for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.06). TransMedics Group had a return on equity of 15.88% and a net margin of 22.69%.The company had revenue of $189.95 million for the quarter, compared to the consensus estimate of $184.00 million. During the same period in the previous year, the firm posted $0.92 EPS. The business’s quarterly revenue was up 20.7% compared to the same quarter last year. On average, analysts anticipate that TransMedics Group will post 1.47 earnings per share for the current fiscal year.

About TransMedics Group

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post?transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.